soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM soul trial oral semaglutide cardiovascular

Click this text to follow Massenomics on Instagram

Optimizar el metabolismo de las grasas y favorecer la prdida de peso

What This Means for CDMO Partners and Clinical Research Programmes For the clinical research and biopharma community, the GLP-1 manufacturing transformation has consequences that extend well beyond the cardiometabolic therapeutic area

Notably, this low dose outperformed even some existing obesity medications at the time, without the troublesome side effects

It belongs to a class of medication called glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Esto significa que pueden haber casos que incluso el aumento haya sido mayor